Rheumatoid Arthritis Drug Discoveries: what the future holds

Publication Date	March 2008
Publisher	Espicom
Product Type	Report
Pages	250
ISBN Number	not applicable
Product Code	ESP00478

Price

£995.00
approximately: $1,478 | €1,171

PDF

PRINT £995 ($1,478 | €1,171)

Order above formats by FAX

Summary

With significant unmet clinical need and the progressive introduction of higher value and effective biopharmaceuticals, the rheumatoid arthritis market is expected to more than double in value to US$27 billion by 2015. This new management report provides a complete examination of the RA market and its prospects in the medium term.

Prevalence and incidence - where in the world?

Rheumatoid arthritis is the most common chronic inflammatory joint disease. The incidence of RA among white populations is approximately 3 people per 10,000 or 0.03 per cent per annum worldwide, although this can vary markedly between different regions. RA is rare in rural and less developed parts of the world; indeed, one large study in Nigeria failed to find a single case of RA. It is also known to be rare in China and Indonesia, and the incidence is very low in Japan, suggesting urbanised and westernised lifestyles may have a key role in the onset of the disease.

RA is relatively uncommon in patients aged less than 15 years, with incidence increasing up to the age of 70 years before tailing off. The commonest age of onset is between 40 and 50 years of age. Overall, the prevalence in North America and the European Union is expected to increase until at least 2010, due to the aging population. At the same time, prevalence in rural countries is expected to continue to increase.

A rising market

We estimate the global rheumatoid arthritis market was worth approximately US$11.6 billion in 2007, accounting for 1.7 per cent of global pharmaceutical sales (which were US$691.2 billion in 2007). Global sales include the non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, traditional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate, (MTX), and the biologic therapies. The biologics account for the greatest proportion of sales, although the majority of patients are still treated with the traditional DMARDs.

By 2015, we expect the global RA market to generate sales of around US$27 billion due to the growth in sales of existing and new biologic therapies, which will remain as the main growth drivers. The new oral therapies will begin to make a further impact on market growth from 2011. The uptake of these more effective newer agents will lead to a decline in sales of established treatments to 2015.

Price pressure and safety: blocks to growth?

Against these possibilities for future market growth, there looms the spectre of the financial strain placed on healthcare systems by the prescription of highly-priced biologics, which may limit their use. In the treatment of RA, the cost of the new biologics is considerably higher than the cost of the traditional treatments. In addition, unexpected safety issues may impact market growth of the RA market as a whole. For instance, the withdrawal of Merck & Co's Vioxx and Pfizer's Bextra has seen a slowdown in the uptake of Cox-2 inhibitors in the treatment of the signs and symptoms of RA.

Questions answered

Who will be the leading players in the RA market in 2015 and what products and approaches will be influential?
What advantages will the new generation of biopharmaceuticals have over existing treatments?
How extensive is Pfizer's development portfolio in RA?
How important will combination therapy be in the RA sector?
Enbrel, Remicade and Humira - who will win the battle for sales, and why?
Evaluation and forecasts for leading therapies and prospects include...

Currently available

Celebrex
Remicade
Humira
Enbrel
Kineret
Rituxan/MabThera
Orencia

Phase III/Filed

Golimumab
Actemra
Cimzia
Ofatumumab
Ocrelizumab

Phase II

CP-690550
CP-195543
TRU-015
SCIO-469
Baminercept
Denosumab
AMG 108
Atacicept
Tamatinib
LymphoStat-B
RhuDex
CF101 SC12267

Content

Introduction
What Is Rheumatoid Arthritis?
- Pathogenesis of Rheumatoid Arthritis
- Classification of Rheumatoid Arthritis
- Assessment of Disease Activity and Response to Treatment
Current Treatment Options
- Diagnosis of Rheumatoid Arthritis
- Pharmacological Therapy
- Treatment Strategies
Patient Statistics
- Incidence and Prevalence
- The Future
The Rheumatoid Arthritis Market
- Players and Products
  - Players and Products in 2007
  - Players and Products in 2015
- Drug Growth Drivers and Dampeners
Analysis of Current Leading Products
- Non-Steroidal Anti-Inflammatory Drugs
  - Arcoxia
  - Mobic
- Glucocorticoids
- Traditional Disease-Modifying Anti-Rheumatic Drugs
- Biological Agents
  - TNF Inhibitors
  - Remicade
  - Humira
  - Enbrel
  - Interleukin-1 Receptor Inhibitor
  - Kineret
  - B-Cell Targeted Therapy
  - Rituxan/MabThera
  - T-Cell Co-Stimulation Modulator
  - Orencia
Research and Development of Rheumatoid Arthritis Drugs
- Late-Phase Projects
  - TNF Inhibitors
  - Cimzia
  - Golimumab
  - Interleukin-6 Receptor Inhibitor
  - Actemra
  - Interleukin-1 Receptor Inhibitor
  - Canakinumab
  - B-Cell Targeted Therapy
  - Ocrelizumab
  - Ofatumumab
  - Non-Steroidal Anti-Inflammatory Drugs
  - Iguratimod
  - PN-400
  - Rheumatoid Arthritis Drug Discoveries
    - Glucocorticoid
    - Lodotra
- Phase Ii Projects
  - Oral Therapies
  - Adenosine Receptor Antagonist
    - CF101
    - Cathepsin-S Inhibitor
    - RWJ-445380
  - Chemokine Receptor Antagonists
    - Selzentry
    - DHODH Inhibitor
    - SC12267
    - Interleukin Inhibitors
    - Apilimod
    - Kinase Inhibitors
    - 681323
    - 856553
    - BMS-582949
    - CP-195543
    - CP-690550
    - INCB18424
    - PH-797804
    - SCIO-469
    - Tamatinib
    - VX-702
    - T-Cell Co-Stimulation Modulator
    - Other Oral Therapies
    - 274150
    - CH-1504
    - CRx-102
    - K-832
    - PMI-001
    - R7277
  - Injectable Therapies
    - B-Cell Targeted Therapy
    - Atacicept
    - LymphoStat-B
    - TRU-015
    - Interleukin Inhibitors
    - AMG 108
    - Lymphotoxin Beta and LIGHT Pathway Inhibitor
    - Baminercept
    - RANK Ligand Inhibitor
    - Denosumab
    - TNF Inhibitor
    - tgAAC94
    - Other Injectable Therapies
    - MM-093
- Phase I Projects
  - Kinase Inhibitors
  - ARRY-438162
  - ARRY-797
  - MLN0415
  - Rheumatoid Arthritis Drug Discoveries
    - Anti-TNF
    - ART621
    - Others
    - PRTX-100
    - VAP-1
Appendix 1: Competitor Ratio Analysis
Appendix 2: Company Profiles
- 4SC
- Abbott
- Amgen
- Arana Therapeutics
- AstraZeneca
- Biogen Idec
- Bristol-Myers Squibb
- Can-Fite Biopharma
- Chelsea Therapeutics
- Chugai
- Dainippon Sumitomo Pharma
- Eisai
- Eli Lilly
- Genmab
- GlaxoSmithKline
- Human Genome Sciences
- Johnson & Johnson
- Kowa Pharmaceutical
- Medigene
- Merck KGaA
- Merrimack Pharmaceuticals
- Millennium Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Novartis
- Phytomedics
- Pozen
- Pfizer
- Rigel Pharmaceuticals
- Roche
- sanofi-aventis
- Schering-Plough
- Synta Pharmaceuticals
- Takeda
- Targeted Genetics
- Toyama Chemical
- Trubion
- Wyeth
- Vertex Pharmaceuticals
Appendix 3: Glossary
Appendix 4: Sources
- Rheumatoid Arthritis Drug Discoveries
Index of Tables
- Traditional DMARDs used in the treatment of RA
- Acr Responses
- Products in Development for The Treatment of Rheumatoid Arthritis
- Competitor Ratio Analysis Scores
- Six- and 12-month ACR responses for RAPID 1
- Six and 12 month mean mTSS changes from baseline for RAPID 1
- Competitor Ratio Analysis Scores
- Competitor Ratio Analysis Summary
Index of Charts
- Synovitis and Joint Destruction in Rheumatoid Arthritis
- Bone Erosion in Untreated Rheumatoid Arthritis
- Current Views on The Pathogenesis of Rheumatoid Arthritis
- Guidelines for The Management of Rheumatoid Arthritis
- Global Rheumatoid Arthritis Drug Sales (2007E)
- Rheumatoid Arthritis Market (2007E-2015E)
- Global Market Share of Major Biologic RA Products (2007E)
- Global Market Share of RA Biologics and Oral Therapies by Sales (2015E)
- Celebrex RA Sales (2008E-2015E)
- Remicade RA Sales (2008E-2015E)
- Humira RA Sales (2008E-2015E)
- Enbrel RA Sales (2008E-2015E)
- Kineret RA Sales (2008E-2015E)
- Rituxan/MabThera RA Sales (2008E-2015E)
- Orencia RA Sales (2008E-2015E)
- Launch of Biologics in Late-Phase Development to Treat Rheumatoid Arthritis
- Cimzia RA Sales (2008E-2015E)
- Golimumab RA Sales (2009E-2015E)
- The Role of IL-6 in Inflammation
- Actemra RA Sales (2008E-2015E)
- Ocrelizumab RA sales (2011E-2015E)
- Ofatumumab RA Sales (2010E-2015E)
- Cf101 Ra Sales (2012e-2015e)
- Sc12267 Ra Sales (2011e-2015e)
- Cp-195543 Ra Sales (2012e-2015e)
- Cp-690550 Ra Sales (2011e-2015e)
- Scio-469 RA Sales (2012E-2015E)
- R788 RA Sales (2011E-2015E)
- RhuDex RA Sales (2012E-2015E)
- Atacicept RA Sales (2011E-2015E)
- LymphoStat-B RA sales (2011E-2015E)
- Tru-015 Ra Sales (2011e-2015e)
- Amg 108 Ra Sales (2011e-2015e)
- Baminercept RA Sales (2010E-2015E)
- Denosumab RA Sales (2009E-2015E)